Literature DB >> 1002996

Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.

H N Fernandez, T E Hugli.   

Abstract

Human C5a was isolated from complement-activated serum and was characterized for protein and carbohydrate content. The purified C5a was judged to be homogeneous by both polyacrylamide gel electrophoresis and immunologic techniques. The polypeptide moiety of C5a contains 73 amino acid residues which represent a m.w. of 8,200. Analysis of the carbohydrate moiety in C5a indicated 4 moles of glucosamine, 3 to 4 moles os sialic acid, 4 moles of mannose and 2 moles of galactose. The total carbohydrate content in C5a, therefore, amounts to approximately 25% of the apparent m.w. of the anaphylatoxin molecule. The protein and carbohydrate portions of C5a together equal a m.w. of approximately 11,000 which is considerably less than the 15 to 16,000 indicated by physical measurements. Human C5a contains a COOH-terminal arginine which is essential for anaphylatoxin activity and a sequence of Gln-Leu-Gly-Arg-COOH at the COOH-terminus which compares favorably with that of human C3a (Gly-Leu-Ala-Arg-COOH). Additional similarities between the C3a and C5a molecules include length of the polypeptide chain, number of disulfide bonds and an absence of tryptophan residues. A major chemical difference does exist between these two human anaphylatoxins, namely that carbohydrate is associated with C5a but is absent in the C3a molecule. The partial NH2-terminal sequence of C5a was determined as NH2-Thr-Leu-Glx-Lys-Ile-Glx-Glx-Ile-Ala- and direct comparison with the known sequence of human C3a shows little homology.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1002996

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  15-hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits the LTB4-induced skin response.

Authors:  T Ternowitz; P H Andersen; P Bjerring; K Fogh; J M Schröder; K Kragballe
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

2.  Rapid micromeasurement of neutrophil exocytosis.

Authors:  R O Webster; P M Henson
Journal:  Inflammation       Date:  1978-06       Impact factor: 4.092

Review 3.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

4.  Transendothelial cell diapedesis of neutrophils in inflamed human skin.

Authors:  C Schubert; E Christophers; O Swensson; T Isei
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

Review 5.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Enhancement of human neutrophil bactericidal activity by chemotactic factors.

Authors:  A C Issekutz; K Y Lee; W D Biggar
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

7.  Monitoring of cytosolic free Ca2+ in C5a-stimulated neutrophils: loss of receptor-modulated Ca2+ stores and Ca2+ uptake in granule-free cytoplasts.

Authors:  R Gennaro; T Pozzan; D Romeo
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.

Authors:  H D Perez; M Lipton; I M Goldstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  C4a: the third anaphylatoxin of the human complement system.

Authors:  J P Gorski; T E Hugli; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

10.  Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

Authors:  J G Curd; M Yelvington; R J Ziccardi; D A Mathison; J H Griffin
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.